Response of eosinophilic fasciitis associated with Waldenström macroglobulinemia to rituximab.
Dermatol Online J
; 27(8)2021 Aug 15.
Article
en En
| MEDLINE
| ID: mdl-34755959
ABSTRACT
Eosinophilic fasciitis (EF) and generalized morphea (GM) are rare and difficult-to-treat sclerosing skin diseases which may occur in association with hematologic disorders. We present a 66-year-old man with EF and associated Waldenström macroglobulinemia who received combination therapy with rituximab (375mg/m2 every other week, gradually extended to every eight weeks), prednisolone (1.25-30mg/d), and methotrexate (7.5-15mg/w). Three months after rituximab initiation, his skin condition improved steadily accompanied by a significant improvement in joint mobility with only mild and transitory flares (observation period 59 months under treatment with rituximab). To date, there are five case reports on rituximab treatment of EF/GM with an association to hypergammaglobulinemia in three of those cases. Therapy effected significant improvement in four patients. Our case adds to the hitherto limited evidence that rituximab may be a promising therapeutic strategy for EF/GM in association with hypergammaglobulinemia.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Macroglobulinemia de Waldenström
/
Eosinofilia
/
Fascitis
/
Rituximab
/
Factores Inmunológicos
Tipo de estudio:
Risk_factors_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Revista:
Dermatol Online J
Asunto de la revista:
DERMATOLOGIA
Año:
2021
Tipo del documento:
Article